gene_symbol
HLA-C
hgnc_id
HGNC:4933
binding_type
receptor ligand recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
The vaccine primes neoantigen-specific CD8+ T cells that recognize tumor cells presenting the mutated peptide in HLA class I (possibly HLA-C) and kill them via perforin/granzyme (and Fas–FasL) pathways; HLA-C alone is not the cytotoxic target.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
On
gated
Off
other_modifier
Peptide loading and presentation to CD8+ T cells
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06751966
disease_id_num_tar_ref
5988
drug_id_num_tar_ref
16236